Status:

UNKNOWN

Translational Approaches to Septic Cardiomyopathy

Lead Sponsor:

Samuel Brown

Collaborating Sponsors:

Euan Ashley

Conditions:

Cardiomyopathies

Sepsis

Eligibility:

All Genders

18+ years

Brief Summary

This translational study will assess the association between septic cardiomyopathy (measured via left ventricular global longitudinal strain) and (a) inflammatory cytokine profiles, and (b) the behavi...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA
  • At least 18 years of age Admitted to the ICU
  • SEPSIS PATIENTS:
  • Sepsis patients must have:
  • Suspected or confirmed infection AND
  • Organ dysfunction as defined by a SOFA \>= 2 above baseline (if no baseline data available, SOFA assumed to be 0)
  • OR
  • SEPTIC SHOCK PATIENTS:
  • AFTER INFUSION OF 20ML/KG CRYSTALLOID OR EQUIVALENT, septic shock patients must have:
  • Suspected or confirmed infection AND
  • Lactate \> 2 mmol/L AND
  • Receiving vasopressors
  • EXCLUSION CRITERIA Known pregnancy Primary diagnosis of acute coronary syndrome Known preexisting heart disease Known severe valvular disease (regurgitation or stenosis)
  • Major cardiac dysrhythmia such as:
  • Ventricular tachycardia (V-tach)
  • Ventricular Fibrillation (V-fib)
  • Third degree heart block (complete hear block or complete AV block)

Exclusion

    Key Trial Info

    Start Date :

    May 19 2017

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    October 27 2019

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT03252613

    Start Date

    May 19 2017

    End Date

    October 27 2019

    Last Update

    December 24 2018

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Stanford University

    Stanford, California, United States, 94305

    2

    Intermoutain Medical Center

    Murray, Utah, United States, 84157